Work

Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine

Year: 2020
Type: article
Abstract: BACKGROUND/AIMS: Few data on the evolution of endoscopic findings are available in patients with acute severe ulcerative colitis (ASUC). The aim of this study was to describe this evolution in a prospective cohort. METHODS: Patients admitted for a steroid-refractory ASUC and included in a randomized trial comparing infliximab and cyclosporine were eligible if they achieved steroid-free clinical remission at day 98. Flexible sigmoidoscopies were performed at baseline, days 7, 42 and 98. Ulcerative colitis endoscopic index of severity (UCEIS) and its sub-scores - vascular pattern, bleeding and ulceration/erosion - were post-hoc calculated. Global endoscopic remission was defined by a UCEIS of 0, and partial endoscopic remission by any UCEIS sub-score of 0. RESULTS: Among the 55 patients analyzed (29 infliximab and 26 cyclosporine), 49 (83%) had UCEIS ≥6 at baseline at baseline. Partial endoscopic remission rates were higher for bleeding than for vascular pattern and for ulcerations/erosions at day 7 (20% vs. 4% and 5% (n = 55); p = .004 and p=.04), for bleeding and ulceration/erosion than for vascular pattern at day 42 [63% and 65% vs. 33% (n=54); p<.001 for both] and at day 98 [78% and 92% vs. 56% (n = 50); p = .007 and p < .001]. Global endoscopic remission rates at day 98 were higher in patients treated with infliximab than with cyclosporine [73% vs. 25% (n = 26 and 24); p < .001]. CONCLUSION: In steroid-refractory ASUC patients responding to a second-line medical therapy, endoscopic remission process started with bleeding remission and was not achieved in half the patients at day 98 for vascular pattern. Infliximab provided a higher endoscopic remission rate than cyclosporine at day 98.
Institutions: Université de Bordeaux, Inserm, Centre Hospitalier Universitaire de Bordeaux, Centre d'Investigation Clinique Plurithématique de Bordeaux, Centre Hospitalier Universitaire de Nantes, Nantes Université, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, Hôpital Beaujon, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire de Rouen, Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau, Université de Rouen Normandie, Centre Hospitalier Universitaire de Besançon, Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Hôpital Saint-Antoine, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Cliniques Universitaires Saint-Luc, UCLouvain, Hospital Universitario Ramón y Cajal, Centre Hospitalier Universitaire Amiens-Picardie, Institut national de l'environnement industriel et des risques, Périnatalité & Risques Toxiques, Université de Picardie Jules Verne, Bicêtre Hospital, Université Clermont Auvergne, Microbe, Intestine, Inflammation and Host Susceptibility, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Louis-Mourier, Centre Hospitalier Universitaire de Saint-Étienne, Universitair Ziekenhuis Leuven, University Hospital Mútua de Terrassa, Mútua Terrassa, University of Helsinki, Helsinki University Hospital, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Sorbonne Université, Hôpital Tenon, Groupe Hospitalier Intercommunal Le Raincy Montfermeil, Ghent University Hospital, Centre Hospitalier Régional et Universitaire de Nancy, Nutrition-Génétique et Exposition aux Risques Environnementaux, Université de Lorraine, Equipe de Recherche en Epidémiologie Nutritionnelle, Centre de Recherche Épidémiologie et Statistique
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,000
OpenAlex ID: W3047809043
FWCI: 2.438
Cites: 32
Cited by: 24
Related to: 10